Retatrutide is the compound the weight-loss research world is watching most closely right now. Here's what it actually is, without the jargon.
The one-sentence version
Retatrutide copies three of your body's own appetite-and-fuel signals at the same time, which is why researchers call it a "triple agonist."
What "agonist" means
An agonist is simply something that switches a body signal on. Think of your body as having a control panel of switches. A single agonist flips one switch. Retatrutide flips three.
The three switches
- GLP-1 — the "I'm full" signal. It's the same pathway semaglutide (Ozempic, Wegovy) works on. It slows how fast your stomach empties and tells your brain you've had enough.
- GIP — a second gut signal involved in how the body handles blood sugar and stores fat. Tirzepatide adds this one on top of GLP-1.
- Glucagon — this is the one that makes retatrutide different. Glucagon is associated with the body burning stored fuel rather than just storing less of it.
Why that third switch matters
Most weight-loss compounds work mainly on the intake side — you eat less. Adding glucagon brings the energy-expenditure side into play too. In published trials, retatrutide has produced some of the largest average weight reductions reported for this class of compound.
Where the science actually stands
This is the part that gets skipped in most articles. Retatrutide is investigational. It is still moving through clinical trials and is not approved as a medicine anywhere. Long-term safety data does not yet exist in the way it does for older GLP-1 compounds.
That is not a knock against it — it's simply where the research is. Anyone telling you retatrutide is proven is getting ahead of the evidence.
How it compares
| Compound | Switches | Status |
|---|---|---|
| Semaglutide | GLP-1 | Approved for specific uses |
| Tirzepatide | GLP-1 + GIP | Approved for specific uses |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational |
The bottom line
Retatrutide is the most mechanistically ambitious compound in the GLP-1 family so far — three signals instead of one or two. It is also the least established. Both things are true at once.
Dissolv supplies retatrutide and related compounds for laboratory research only. These materials are not medicines, are not for human or veterinary consumption, and have not been evaluated by the FDA for safety or effectiveness in people. This article is educational and is not medical advice, dosing guidance, or a promise of results.
